['atopic dermatitis']
['nemolizumab', 'placebo']

        Inclusion Criteria:

          -  Male or female subjects ≥ 18 years (or legal age when higher)

          -  Chronic AD, that has been present for at least 2 years before the visit

          -  Eczema Area and Severity Index (EASI) score ≥12

          -  Investigator Global Assessment (IGA) score ≥ 3

          -  AD involvement ≥ 10% of Body Surface Area (BSA)

          -  Severe pruritus on at least 3 of the last 7 days before the visit

          -  Documented recent history (within 6 months before the visit) of inadequate response to
             topical medications

          -  Female subjects must fulfill one of the criteria below:

               -  Female subjects of non-childbearing potential

               -  Female subjects of childbearing potential who agree to a true abstinence or to
                  use an effective or highly effective method of contraception throughout the
                  clinical trial and for 120 days after the last study drug administration

        Exclusion Criteria:

          -  Body weight < 45 kg

          -  subjects with a medical history of asthma requiring hospitalization in the last 12
             months before screening visit and/or whose asthma has not been well-controlled during
             the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) <80% of
             the predicted value

          -  Cutaneous bacterial or viral infection within 1 week before the screening visit or
             during the run-in period

          -  Infection requiring treatment with oral or parenteral antibiotics, antivirals,
             antiparasitics or antifungals within 1 week before the screening visit or during the
             run-in period

          -  History of intolerance to low or mid potency TCS or for whom TCS is not advisable
      